Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Which of These COPD Treatments Will Come Out on Top?

Page 1 of 2

To most people, cigarettes are often associated with lung cancer. However, smoking also causes other severe respiratory problems, such as COPD (chronic obstructive pulmonary disease). COPD occurs as a result of emphysema, which breaks down lung tissues — causing chronic cough, increased sputum production, and shortness of breath. COPD is currently the third leading cause of death in the United States, and is estimated to cost the country $42.6 billion in healthcare and productivity costs annually. Unlike asthma, COPD is hard to reverse, and generally worsens over time.

Traditional treatments for COPD include inhaled bronchodilators, vaccinations, oxygen therapy, and rehabilitation. However, most of these treatments are considered inadequate, with a high degree of “exacerbations” in which patients’ conditions gradually worsen. Therefore, Wall Street perked up on news that three major pharmaceutical companies are introducing some new COPD treatments for this under-penetrated market.

Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK)

Theravance Inc (NASDAQ:THRX) primarily focuses on treatments for respiratory disease, bacterial infections, and central nervous system ailments. However, it mostly relies on strategic collaborations with larger companies to help cover R&D and marketing costs. Theravance’s primary pulmonary and respiratory programs — Revlar/Breo, Anoro, and Maba — were all developed through partnerships with GlaxoSmithKline plc (ADR) (NYSE:GSK).

Theravance Inc (NASDAQ:THRX)Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK)’s main CPOD treatment, Breo Ellipta (also known as Revlar Ellipta), was approved by the FDA in May. It is the first once-daily inhaled corticosteroid long-acting treatment for COPD. Since its approval, Theravance shares have risen 17%. Breo Ellipta is a long-term maintenance therapy for COPD sufferers, designed to reduce airflow obstructions and exacerbations. The drug is expected to hit the market in the third or fourth quarter this year.

Not a one-trick pony

However, investors shouldn’t dismiss Theravance Inc (NASDAQ:THRX) as another one-trick pony biotech stock. The company still generates substantial revenue from its other treatments, which helped it post a narrower than expected loss of $0.37 per share last quarter. This was a slight improvement over the loss of $0.42 it reported in the prior year quarter, and also topped analyst estimates by $0.22 per share. Revenue, however, declined slightly from $1.4 million to $1.3 million, falling short of the $4 million that analysts had expected.

Theravance Inc (NASDAQ:THRX) also has other treatments in its development pipeline, including treatments for bacterial infections and ADHD, but its respiratory drugs remain the primary reason for investing in the company. However, the company’s aggressive development of its pipeline caused R&D expenses to rise 7.4% year-on-year to $31.7 million, while general and administrative expenses spiked 50% to $11.4 million due to higher legal and accounting costs.

Theravance Inc (NASDAQ:THRX) is also gearing up to split into two separate publicly traded companies, Royalty Management Company and Theravance Biopharma. Royalty Management will retain the development of respiratory candidates, while Theravance will focus on the discovery, development, and commercialization of small-molecule therapies focusing on untapped markets.

Novartis nipping at their heels

Another rising name in COPD treatments is diversified pharma giant Novartis AG (ADR) (NYSE:NVS). Novartis has been developing a once-daily bronchodilator inhaler, known as the Ultibro Breezhaler, aimed at relieving the symptoms of COPD. Ultibro was developed through a combination of two bronchodilators – indacaterol and glycopyrronium bromide, which significantly decreased the rate of exacerbations during clinical trials. Indacaterol relaxes the muscles of the airways as glycopyrronium dilates them.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!